ReviewClinical immunology (Orlando, Fla.)2016
Metastatic melanoma and immunotherapy.
Review in Clinical immunology (Orlando, Fla.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.Oncoimmunology · 2021Trial
- Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cell Death Modalities in Therapy of Melanoma.International journal of molecular sciences · 2025Review
- Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.Molecular cancer · 2025Review
- Local sympathetic nerve depletion does not alter vitiligo progression in a mouse model.Frontiers in medicine · 2025Article
- Primary spinal melanoma with special imaging appearances and pathologic characteristics: surgical treatment for two cases in a single center.Acta neurologica Belgica · 2024Article
- The combination of single-cell and RNA sequencing analysis decodes the melanoma tumor microenvironment and identifies novel T cell-associated signature genes.Journal of Cancer · 2024Article
- Review
- Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.Frontiers in pharmacology · 2023Review
- Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.Frontiers in immunology · 2023Article
- Malignant Melanoma Presenting as Spinal Cord and Pleural Lesions.Case reports in oncological medicine · 2023Article
- Integration of lncRNAs, Protein-Coding Genes and Pathology Images for Detecting Metastatic Melanoma.Genes · 2022Article
- A mouse model of vitiligo based on endogenous auto-reactive CD8 + T cell targeting skin melanocyte.Cell regeneration (London, England) · 2022Article
- Anti-Gr-1 Antibody Provides Short-Term Depletion of MDSC in Lymphodepleted Mice with Active-Specific Melanoma Therapy.Vaccines · 2022Article
- Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.Scientific reports · 2022Article
- Article
- Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.Frontiers in immunology · 2022Article
- Mechanisms of immune checkpoint inhibitor-mediated liver injury.Acta pharmaceutica Sinica. B · 2021Review
- Rethinking the biology of metastatic melanoma: a holistic approach.Cancer metastasis reviews · 2021Review
- FcγRIIB is a T cell checkpoint in antitumor immunity.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Harnessing the immune system to attack cancer cells has represented a holy grail for greater than 100years. While prospects of tumor-selective durable immune based therapies have provided small clinical signals for many decades, recent years have demonstrated a virtual explosion in progress. Melanoma has led the field of cancers in which immunotherapy has produced major clinical inroads. The most significant and impactful immunotherapies for melanoma utilize immune checkpoint inhibition to stimulate T cell mediated tumor killing. The major targets of checkpoint blockade have thus far been CTLA4 and PD1, two key receptors for central and peripheral immune tolerance. This review discusses current understanding of how these checkpoint blockade therapeutics have led to major clinical responses in patients with advanced melanoma. It is likely that we are poised to see significantly greater anti-cancer immunotherapy efficacy, both in improving response rates and durability for melanoma, and for other less immunogenic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.